ReviewJournal of clinical medicine2022
Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 27 citations in OpenAlex.
- Leukocytoclastic Vasculitis Presenting With Peripheral Neuropathy and Foot Drop in an Adolescent: A Case Report.Cureus · 2026Article
- Leukocytoclastic vasculitis and necrobiotic pulmonary nodules in endoscopic remission of ulcerative colitis.JPGN reports · 2026Article
- Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.Inflammatory bowel diseases · 2026Review
- Leukocytoclastic Vasculitis Occurring During Upadacitinib Therapy in Ulcerative Colitis: A Case Report.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Annular leukocytoclastic vasculitis associated with isolated anti-β2 glycoprotein I immunoglobulin G positivity: A case report.SAGE open medical case reports · 2026Article
- Successful treatment of cutaneous small-vessel vasculitis with upadacitinib: a Case Report.Frontiers in medicine · 2026Article
- Acute Genitourinary Pain and Swelling in a Child-Look Out for the Rashes!Pediatric discovery · 2025Article
- Article
- Cutaneous small vessel vasculitis in the COVID-19 era: a systematic review.Skin health and disease · 2025Review
- Lobetyolin ameliorates DSS-induced ulcerative colitis in mice by alleviating inflammation, restoring barrier function, and modulating gut microbiota-metabolite interactions.Frontiers in microbiology · 2025Article
- Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Following Initiation of Sulfasalazine for Ulcerative Colitis: A Yearlong Clinical Challenge.Case reports in gastrointestinal medicine · 2025Article
- Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review.Rheumatology international · 2024Review
- Pyoderma gangrenosum-like lesions in the setting of IgA cutaneous vasculitis: Favourable response to adalimumab.Skin health and disease · 2024Article
- Article
- Review
- Reactive Angioendotheliomatosis in Association with Ulcerative Colitis.Case reports in dermatological medicine · 2024Article
- Atypical Immunoglobulin A Vasculitis in a Pediatric Patient With Ulcerative Colitis.ACG case reports journal · 2023Article
- Leukocytoclastic Vasculitis Secondary to Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases: A Multicenter Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project.Biomedicines · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukocytoclastic vasculitis (LCV) is a rare extraintestinal manifestation (EIM) of ulcerative colitis (UC). Observations about its association with UC stem from case reports and small case series. Due to its rarity, more rigorous cross-sectional studies are scarce and difficult to conduct. The aim of this systematic review was to synthetize the knowledge on this association by reviewing published literature in the form of both case reports and case series; and report the findings according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In contrast to LCV in Chron disease (CD), which occurs secondary to biologic therapies used for its treatment, LCV in UC is a true reactive skin manifestation. Both genders are equally affected. Palpable purpura (41%) and erythematous plaques (27%) are the most common clinical manifestations. In 41% of patients, the rash is painful, and the lower extremities are most commonly involved (73%). Systemic symptoms such as fever, arthralgias, fatigue, and malaise are seen in 60% of patients. Unlike previous reports, we found that LCV more commonly occurs after the UC diagnosis (59%), and 68% of patients have active intestinal disease at the time of LCV diagnosis. Antineutrophil cytoplasmic antibody (ANCA) is positive in 41% of patients, and 36% of patients have other EIMs present concomitantly with LCV. The majority of patients were treated with corticosteroids (77%), and two (10%) required colectomy to control UC and LCV symptoms. Aside from one patient who died from unrelated causes, all others survived with their rash typically resolving without scarring (82%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.